Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anne-Flore Plane

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
JACC. Case Reports|July 28, 2021
Occluded or Not?: A Subtle Electrocardiographic AnswerAnne-Flore Plane, Xavier Valette, Katrien Blanchart, et al.
Leukemia|September 19, 2024
Is ibrutinib-related atrial fibrillation dose dependent? Insights from an individual case level analysis of the World Health Organization pharmacovigilance databaseJoachim Alexandre, Jonaz Font, Da-Silva Angélique, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|April 24, 2025
Identification of Anticancer Drugs Associated to Cancer Therapy-Related Cardiac Dysfunction: A VigiBase® Disproportionality AnalysisDamien Legallois, Angélique Da Silva, Joachim Alexandre, et al.
JACC. Cardiooncology|May 5, 2023
Atrial Fibrillation Incidence Associated With Exposure to Anticancer Drugs Used as Monotherapy in Clinical TrialsJoachim Alexandre, Louis Boismoreau, Pierre-Marie Morice, et al.
European Heart Journal|September 16, 2021
Cardiovascular immunotoxicities associated with immune checkpoint inhibitors: a safety meta-analysisCharles Dolladille, Julia Akroun, Pierre-Marie Morice, et al.
Archives of Cardiovascular Diseases|May 19, 2020
Cardiovascular safety of rapidly accelerated fibrosarcoma B-type and/or mitogen-activated extracellular signal-regulated kinase inhibitors: A mixed approach combining a meta-analysis and a pharmacovigilance disproportionality analysisCharles Dolladille, Jonaz Font, Theodora Bejan-Angoulvant, et al.
Fundamental & Clinical Pharmacology|March 12, 2018
PAR1 contribution in acute electrophysiological properties of oral anticoagulants in rabbit pulmonary vein sleeve preparationsJonaz Font, Mathilda Simeon, Christophe Simard, et al.
Journal for Immunotherapy of Cancer|January 29, 2020
Late cardiac adverse events in patients with cancer treated with immune checkpoint inhibitorsCharles Dolladille, Stephane Ederhy, Stéphane Allouche, et al.
Biomedicines|September 27, 2025
Association Between the Renin-Angiotensin System and Ibrutinib-Related Cardiovascular Adverse Events: A Translational Cohort StudyJonaz Font, Amir Hodzic, Angélique Da-Silva, et al.
JAMA Oncology|April 17, 2020
Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With CancerCharles Dolladille, Stéphane Ederhy, Marion Sassier, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
JACC. Case Reports|July 28, 2021
Occluded or Not?: A Subtle Electrocardiographic AnswerAnne-Flore Plane, Xavier Valette, Katrien Blanchart, et al.
Leukemia|September 19, 2024
Is ibrutinib-related atrial fibrillation dose dependent? Insights from an individual case level analysis of the World Health Organization pharmacovigilance databaseJoachim Alexandre, Jonaz Font, Da-Silva Angélique, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|April 24, 2025
Identification of Anticancer Drugs Associated to Cancer Therapy-Related Cardiac Dysfunction: A VigiBase® Disproportionality AnalysisDamien Legallois, Angélique Da Silva, Joachim Alexandre, et al.
JACC. Cardiooncology|May 5, 2023
Atrial Fibrillation Incidence Associated With Exposure to Anticancer Drugs Used as Monotherapy in Clinical TrialsJoachim Alexandre, Louis Boismoreau, Pierre-Marie Morice, et al.
European Heart Journal|September 16, 2021
Cardiovascular immunotoxicities associated with immune checkpoint inhibitors: a safety meta-analysisCharles Dolladille, Julia Akroun, Pierre-Marie Morice, et al.
Archives of Cardiovascular Diseases|May 19, 2020
Cardiovascular safety of rapidly accelerated fibrosarcoma B-type and/or mitogen-activated extracellular signal-regulated kinase inhibitors: A mixed approach combining a meta-analysis and a pharmacovigilance disproportionality analysisCharles Dolladille, Jonaz Font, Theodora Bejan-Angoulvant, et al.
Fundamental & Clinical Pharmacology|March 12, 2018
PAR1 contribution in acute electrophysiological properties of oral anticoagulants in rabbit pulmonary vein sleeve preparationsJonaz Font, Mathilda Simeon, Christophe Simard, et al.
Journal for Immunotherapy of Cancer|January 29, 2020
Late cardiac adverse events in patients with cancer treated with immune checkpoint inhibitorsCharles Dolladille, Stephane Ederhy, Stéphane Allouche, et al.
Biomedicines|September 27, 2025
Association Between the Renin-Angiotensin System and Ibrutinib-Related Cardiovascular Adverse Events: A Translational Cohort StudyJonaz Font, Amir Hodzic, Angélique Da-Silva, et al.
JAMA Oncology|April 17, 2020
Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With CancerCharles Dolladille, Stéphane Ederhy, Marion Sassier, et al.
Pageof 2